Researchers from The University of Texas MD Anderson Cancer Center have found qigong, an ancient mind-body practice, reduces depressive symptoms and improves quality of life in women undergoing radiotherapy for breast cancer.
Prototype drug stabs membranes to kill microbes that cause pneumonia, sepsis, other infections.
Marked for death with molecular tags that act like a homing signal for a cell’s protein-destroying machinery, a pivotal enzyme is rescued by another molecule that sweeps the telltale targets off in the nick of time.
From a single cell gone bad, cancer evolves into an increasingly complex tumor built of a variety of normal cells and diverse malignant cells, some of which escape to create dangerous colonies in other organs, further jumbling the treatment picture.
FDA approves ponatinib, third drug in four months; all clinical trials led by MD Anderson.
An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.
Adults with a New Year resolution to eat healthier foods that can potentially lower cancer risks are invited to participate in the 2013 Healthy Bites nutrition challenge, developed by experts at MD Anderson Cancer Center.
Donated umbilical cord blood establishes a new blood supply in patients more quickly after transplantation when it is first expanded in the lab on a bed of cells that mimics conditions in the bone marrow, researchers report in the Dec. 13 edition of the New England Journal of Medicine.
A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ASH Annual Meeting and Exposition.
A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer.
Researchers from The University of Texas MD Anderson Cancer Center found statins, the commonly used drug to lower cholesterol, improved progression-free survival in patients with inflammatory breast cancer (IBC).
African American women with early stage, invasive breast cancer were 12 percent less likely than Caucasian women with the same diagnosis to receive a minimally invasive technique, axillary sentinel lymph node (SLN) biopsy, years after the procedure had become the standard of surgical practice, according to research from The University of Texas MD Anderson Cancer Center.
Phase I trial shows third-generation drug helps patients after other treatments fail.
PKM2 slips into nucleus to promote cancer; potential biomarker and drug approach discovered.
Adults can avoid holiday weight gain by stocking up on the cancer-fighting foods listed in the new Holiday Food Grocery List, created by experts at MD Anderson Cancer Center.
Drug from scientist’s research helps the immune system recognize and destroy malignant cells
Doxorubicin, a 50-year-old chemotherapy drug still in widespread use against a variety of cancers, has long been known to destroy heart tissue, as well as tumors, in some patients.
Two studies led by The University of Texas MD Anderson Cancer Center have found that proton therapy preserves the quality of life, specifically urinary and bowel function, in men treated with this targeted radiation modality for prostate cancer.
Low depressive symptoms and a longer telomere length are compelling factors that contribute to a prolonged life for bladder cancer patients according to researchers at The University of Texas MD Anderson Cancer Center.
Enzyme levels in the blood routinely monitored by physicians as liver function indicators are also the best predictor of liver cancer risk for the general population, a team of scientists in Taiwan and The University of Texas MD Anderson Cancer Center reports today in the Journal of the National Cancer Institute.
Lynda Chin, M.D., professor and chair of Genomic Medicine and scientific director of the Institute for Applied Cancer Science at The University of Texas MD Anderson Cancer Center, has been elected to the Institute of Medicine (IOM) of the National Academies.
Obesity is a growing concern, not only in healthy children, but among pediatric cancer patients and survivors.
A receptor protein suppresses local invasion and metastasis of breast cancer cells, the most lethal aspect of the disease, according to a research team headed by scientists from The University of Texas MD Anderson Cancer Center.
Pam Redden, director of clinical operations development at The University of Texas MD Anderson Cancer Center, is the recipient of the 2012 Julie and Ben Rogers Award for Excellence in Administration.
The University of Texas MD Anderson Cancer Center announces the launch of the Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.
A Nature Medicine study describes the discovery of a novel drug combination aimed at a subset of melanoma patients who currently have no effective therapeutic options. About one-fourth of melanoma patients have NRAS-mutant tumors. For the first time, this study provides new hope for these patients that an effective targeted treatment might be developed by combining Mek and Cdk4 inhibitors.
Largest systematic review provides the most current information on class of drugs available to patients.
A metabolic protein that nourishes cancer cells also activates tumor-promoting genes by loosening part of the packaging that entwines DNA to make up chromosomes, a team led by scientists at The University of Texas MD Anderson Cancer Center reports in the Aug. 16 issue of Cell.
Passenger deletions that deactivate essential genes provide new opportunity to strike cancer.
Findings contrary to current treatment guidelines.
Inflammatory pathways key to understanding the relationship.
It’s been a burning question in melanoma research: Tumor cells are full of ultraviolet (UV)-induced genetic damage caused by sunlight exposure, but which mutations drive this cancer?
For the sixth consecutive year, The University of Texas MD Anderson Cancer Center has been named the nation's top hospital for cancer care, according to the "Best Hospitals" survey published annually by U.S. News & World Report magazine.
Dorothy I. Height devoted her life to education, civil rights and women's rights. Her legacy and passion for improving the lives of Americans continues with the naming of the Dorothy I. Height Center for Health Equity and Evaluation Research (CHEER) - a collaboration between The University of Texas MD Anderson Cancer Center and the University of Houston.
Once considered merely a passive link between proteins that matter, Grb2 - pronounced "grab2" - actually lives up to its nickname with its controlling grip on an important cell signaling pathway, scientists at The University of Texas MD Anderson Cancer Center report in the June 22 issue of Cell.
A Texas ranch girl who went on to travel the world with her husband, James A. Baker III, Susan Garrett Baker will headline The University of Texas MD Anderson Cancer Center's 24th annual Anderson Network Cancer Survivorship Conference Sept. 14-15 at the Omni Westside, 13210 Katy Freeway.
Presence of normal p53, a tumor suppressor gene, instead of a mutated version, makes breast cancer chemotherapy with doxorubicin less effective. The preclinical study led by MD Anderson scientists was published today in the journal Cancer Cell.
Claudine Jreissaty, RN, of The University of Texas MD Anderson Cancer Center, is the recipient of the 2012 Ethel Fleming Arceneaux Outstanding Nurse-Oncologist Award. Established by The Brown Foundation, Inc. in 1982, the award is the institution's highest nursing honor.
E3 ligase’s role makes it target for defeating Herceptin resistance, stifling cancer’s preferred diet.
May 9 luncheon honors Right Honourable Tony Blair in interview with Greta Van Susteren, raising more than $773,000.
Three-pronged study reveals high response rate in other advanced melanoma patients and activity in multiple cancers.
Novel adjuvant therapy shows promise for women with a history of breast cancer in Phase II clinical trial.
Cell surface protein GD2 blows potent tumor-generating cells’ cover. The first single marker of breast cancer stem cells also is targetable by a drug in preclinical tests.
The University of Texas MD Anderson Cancer Center and the Norwegian Cancer Consortium (NCC) will host the 2012 Global Academic Programs (GAP) Conference May 14-16, in Oslo, Norway. The annual conference brings together hundreds of oncologists, researchers and students from a growing, global network to strengthen research and academic collaborations.
The University of Texas MD Anderson Cancer Center will renew a collaborative agreement with the Norwegian Cancer Consortium (NCC) at a signing ceremony scheduled for Saturday, May 12 in Stavanger, Norway.
Sunscreen labels can be confusing and at times misleading. That’s why dermatologists at The University of Texas MD Anderson Cancer Center applaud the upcoming U.S. Food and Drug Administration (FDA) label changes that help consumers understand exactly what they’re buying.
Cells resist hormone inhibition and chemotherapy; video captures production of other cell types.
The University of Texas MD Anderson Cancer Center President Ronald DePinho, M.D., has been elected to the National Academy of Sciences (NAS) - one of the most prestigious accolades in the United States bestowed in the field of science and engineering.
Greta Van Susteren, host of Fox News Channel’s “On the Record With Greta Van Susteren,” will interview the Right Honorable Tony Blair, former Prime Minister of Great Britain and Northern Ireland, at the 23rd annual A Conversation With a Living Legend® May 9 in Dallas. This year’s luncheon, supported by business and community leaders in the Dallas-Fort Worth area, already has raised $788,000 for research and patient care initiatives at The University of Texas MD Anderson Cancer Center.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right